Enanta Pharmaceuticals Inc represents values of innovation, expertise, and commitment to patient care. As a leading research and development company in the pharmaceutical industry, Enanta focuses on discovering and developing small molecule drugs for viral infections and liver diseases. The company's corporate philosophy revolves around harnessing its deep scientific knowledge, cutting-edge technology, and strategic partnerships to address unmet medical needs. Enanta's dedication to advancing patient well-being through the development of effective and safe therapies is evident in its portfolio of innovative drugs and its commitment to delivering value to patients, healthcare providers, and shareholders.

Enanta Pharmaceuticals Inc is primarily present in the United States.

Enanta Pharmaceuticals Inc has achieved significant milestones in its history. Some noteworthy accomplishments include the development and successful commercialization of innovative therapies in the field of infectious diseases, particularly Hepatitis C (HCV) and respiratory tract infections. Enanta Pharmaceuticals Inc gained recognition for its contribution towards the discovery and development of direct-acting antiviral agents for HCV treatment. The company's achievements also encompass the advancement of its proprietary chemistry technology platform, enabling the discovery of novel small molecule drugs. With a commitment to scientific excellence and robust partnerships, Enanta Pharmaceuticals Inc continues to make remarkable strides in advancing the field of pharmaceutical research and development.

Enanta Pharmaceuticals Inc is a biotechnology company specializing in the research and development of small molecule drugs for viral infections and liver diseases. Founded in 1995, Enanta has made significant contributions in the development of antiviral therapies, particularly for hepatitis C virus (HCV). The company's innovative approach and strong scientific expertise have led to successful collaborations with leading pharmaceutical companies. Enanta's dedication to discovering breakthrough treatments has earned them a reputable position in the biopharmaceutical industry. With a focus on addressing unmet medical needs, Enanta Pharmaceuticals Inc continues to make valuable contributions to the field of drug discovery and development.

The main competitors of Enanta Pharmaceuticals Inc in the market include AbbVie Inc., Gilead Sciences, Inc., and Bristol-Myers Squibb Company.

Enanta Pharmaceuticals Inc is primarily active in the healthcare and pharmaceutical industries.

The business model of Enanta Pharmaceuticals Inc. revolves around discovering, developing, and commercializing small molecule drugs for the treatment of viral infections and liver diseases. Enanta focuses on the research and development of innovative antiviral therapies, utilizing its expertise in infectious diseases. By leveraging its proprietary technology platforms and strong scientific capabilities, Enanta aims to create effective and safe therapeutics that address critical unmet medical needs. The company collaborates with pharmaceutical partners to bring its drugs to market, generating revenue through licensing and milestone payments, as well as royalties on product sales. Enanta Pharmaceuticals Inc. strives to improve patient outcomes and enhance the quality of life through its innovative drug development efforts.

P/E odnos Enanta Pharmaceuticals iznosi -2,08.

KUV kompanije Enanta Pharmaceuticals iznosi 3,26.

AlleAktien kvalitativni skor za Enanta Pharmaceuticals je 3/10.

očekivana Enanta Pharmaceuticals promet je 72,64 mil. USD.

Dobit očekivana Enanta Pharmaceuticals je -114,09 mil. USD.

Enanta Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of molecules for the treatment of infectious diseases and other chronic conditions. The company is headquartered in Watertown, Massachusetts and was founded in 1995. Enanta Pharmaceuticals is listed on the NASDAQ stock exchange and employs over 200 employees. The company has three main focuses: Hepatitis C, Respiratory diseases, and NASH/fibrotic diseases. Enanta has developed several patented technologies that are used in the discovery and development of new drugs for these conditions. Among the products Enanta has developed, are some that are already on the market and others that are still in the development phase. In the Hepatitis C division, Enanta has launched a Noviruses-based product that has proven to be effective in the treatment of Hepatitis C. Currently, the company is also working on the development of RNA interference drugs for the treatment of Hepatitis C patients who do not respond to antiviral therapies. Enanta's Respiratory division focuses on the development of molecules for the treatment of respiratory infections. The company has already developed a product that is effective in the treatment of acute bacterial exacerbations (ABECB). Enanta is also working on the development of drugs for the treatment of seasonal and pandemic influenza and other Respiratory Syncytial Virus (RSV) infections. Enanta's research and development in the field of NASH/fibrotic diseases focuses on the development of molecules that can inhibit inflammatory processes in the liver and reduce fibrosis. Currently, Enanta is still in the development phase of drugs for the treatment of NASH/fibrosis. Enanta Pharmaceuticals' business model is based on collaboration with large pharmaceutical companies in the development and commercialization of molecules developed through Enanta's own research and development. Enanta also collaborates with academic institutions and research facilities to identify new molecules for development. Enanta also focuses on the development of drugs for unmet medical needs in the field of infectious diseases and chronic conditions. The company is committed to developing new molecules through innovative research and development to address serious health issues in the world. In summary, Enanta Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of molecules for the treatment of infectious diseases and chronic conditions. With a focus on Hepatitis C, Respiratory diseases, and NASH/fibrosis, Enanta has already brought proven products to the market and is working on the development of new products to meet unmet medical needs. The company collaborates closely with large pharmaceutical companies, academic institutions, and research facilities to conduct innovative research and development and improve the health of the global community.

Enanta Pharmaceuticals isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Enanta Pharmaceuticals trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Enanta Pharmaceuticals je US29251M1062.

WKN od Enanta Pharmaceuticals je A1T7BJ.

Oznaka za praćenje akcija kompanije Enanta Pharmaceuticals je ENTA.

U poslednjih 12 meseci, Enanta Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Enanta Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Enanta Pharmaceuticals trenutno iznosi .

Enanta Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Enanta Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Enanta Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Enanta Pharmaceuticals od 21. 9. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 21. 9. 2024..

Isplata poslednje dividende izvršena je 21. 9. 2024..

U godini 2023 kompanija Enanta Pharmaceuticals je isplatila 0 USD kao dividende.

Dividende od Enanta Pharmaceuticals se isplaćuju u USD.